Table 1

Comparison of characteristics between patients with and without GCs

CharacteristicsWithout
GCs
(n=50)
Number of missing dataWith
GCs
(n=918)
Number of missing dataP value
Age, median IQR, years50.5 (40.8–60.5)044.5 (34–56)00.012
Female patients, n (%)42 (84)0807 (88)00.41
Disease duration, median IQR, years*13 (6–22.5)112 (6–20)200.41
 <5 years, n (%)11 (22)222 (25)
 5–20 years, n (%)23 (47)445 (50)
 ≥20 years, n (%)15 (31)231 (26)
SLEDAI-2K, median IQR*2 (0–6)942230.027
SLICC-DI, median IQR*0 (0–2)01 (0–2)00.61
Maximum PSL dose after diagnosis, median IQR, mg/day50 (30–60)040 (30–50)700.48
Current immunosuppressant use, n (%)21 (42)0596 (65)00.0010
Current hydroxychloroquine use, n (%)2 (4)0262 (29)0<0.0001
C3, median IQR, mg/dL88 (75.5–103.0)480 (68–93)800.033
C4, median IQR, mg/dL17.65 (14.4–22.3)416 (11–21.9)1440.12
CH50, median IQR, U/mL37.6 (32.8–46.6)437 (29.8–44.6)1260.20
Anti-ds-DNA antibody, median IQR, EU/mL7.6 (1.7–10.1)39.15 (2.4–20.8)240.23
Serum creatinine, median IQR, mg/dL0.66 (0.60–0.74)10.69 (0.59–0.84)20.31
  • *Mann-Whitney U test.

  • ds-DNA, double stranded DNA; GC, glucocorticoid; PSL, prednisolone; SLEDAI-2K, SLE Disease Activity Index 2000; SLICC-DI, Systemic Lupus International Collaborating Clinics Damage Index.